Altimmune, Inc. (ALT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Jerome Benedict Durso
|
Chairman, CEO & President | 50.94k | -- | 1968 |
|
Dr. M. Scot Roberts Ph.D.
|
Chief Scientific Officer | 683.23k | -- | 1959 |
|
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.
|
Chief Medical Officer | 361.36k | -- | 1963 |
|
Mr. Gregory L. Weaver CPA, M.B.A.
|
Chief Financial Officer | -- | -- | 1956 |
|
Mr. Richard Menziuso
|
VP, Global Controller & Principal Accounting Officer | -- | -- | 1975 |
|
Mr. Bertrand Georges Ph.D.
|
Chief Technology Officer | -- | -- | -- |
|
Mr. Luis Sanay C.F.A.
|
Vice President of Investor Relations | -- | -- | -- |
|
Mr. Tony Blandin B.S.
|
Vice President of Quality & Compliance Management | -- | -- | -- |
|
Ms. Robin E. Abrams J.D.
|
Chief Legal Officer & Corporate Secretary | -- | -- | 1964 |
|
Mr. Raymond M. Jordt M.B.A., M.S.
|
Chief Business Officer | 578.85k | -- | 1973 |
Altimmune, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 57
Description
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Altimmune, Inc. Earnings Date
